Mounjaro and Zepbound Are No Longer in Shortage, F.D.A. Says
The announcement will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded versions of the medications.
Call for more information
888-531-0245
info@siii-clinical.com
From research laboratories to clinical settings, SIII integrates the technologies, resources, and expertise our customers need to rise to the next opportunity. SIII is dedicated to exploring and researching the processes and scientific mechanisms underlying the world we live in.